文献速递免疫规划传染病防控与疫情报告

表达稳定融合前构象SARS-CoV-2刺突蛋白的包膜病毒样颗粒疫苗可诱导高效免疫

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
PubMed 文献 · Vaccine · 2021-07-16

研究评估了表达不同形式SARS-CoV-2刺突蛋白的包膜病毒样颗粒(eVLP)及多种佐剂,筛选出表达修饰融合前构象刺突蛋白的eVLP单针免疫小鼠后诱导高滴度结合抗体和中和活性。该候选疫苗VBI-2902a与磷酸铝佐剂配伍后单针免疫可平衡诱导IgG2和IgG1亚型,抗体结合和中和滴度在单次免疫后3个多月内未下降,单剂VBI-2902a可保护叙利亚金黄地鼠免受SARS-CoV-2攻击。

要点

  • 表达修饰融合前构象刺突蛋白的eVLP单针免疫小鼠可诱导高滴度结合抗体和中和活性。
  • VBI-2902a与磷酸铝佐剂配伍单针免疫后抗体结合和中和滴度3个多月未下降。
  • 单剂VBI-2902a可保护叙利亚金黄地鼠免受SARS-CoV-2攻击。

核心结论

  • 表达稳定融合前构象SARS-CoV-2刺突蛋白的eVLP候选疫苗VBI-2902a单针免疫可诱导持久高效免疫并保护动物免受攻击。

研究设计与样本

  • 在 mice 中评估表达不同形式SARS-CoV-2刺突蛋白的eVLP及多种佐剂,筛选后在小鼠和叙利亚金黄地鼠中评价候选疫苗VBI-2902a。

主要发现

  • 表达修饰融合前构象刺突蛋白的eVLP单针免疫小鼠后诱导高抗体结合滴度和中和活性。
  • VBI-2902a与磷酸铝佐剂配伍后平衡诱导IgG2和IgG1亚型,单次免疫后抗体结合和中和滴度3个多月未下降。
  • 单剂VBI-2902a保护叙利亚金黄地鼠免受SARS-CoV-2攻击。

临床怎么用

  • 支持VBI-2902a作为高效COVID-19疫苗候选进行正在开展的临床评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fluckiger AC, Ontsouka B, Bozic J, et al. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Vaccine. 2021. PMID: 34304928. doi:10.1016/j.vaccine.2021.07.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。